This biotech small-cap's grown its dividend by 140% since 2016! So with an 8.3% yield, is now the time to add it to my Stocks ...

As of Friday, January 23, Coherus Oncology, Inc.’s CHRS share price has surged by 21.70%, which has investors questioning if ...

As of Friday, January 23, Jade Biosciences, Inc.’s JBIO share price has dipped by 5.64%, which has investors questioning if ...

To this day, animal testing remains one of the most controversial issues in animal rights. Activists have been fighting ...

Berger has participated in meetings (lectures, advisory boards, consultations) sponsored and compensated by pharmaceutical ...

This week's report explores the pharmaceutical industry’s evolution toward resilient, scalable systems that prioritize ...

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...

Confused about childhood vaccines in 2026? This expert-backed guide explains what shots your child needs, when they need them, how schedules have changed, and what today’s political climate means for ...

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)Nantes, France, January 21, 2026 – 6pm CET - OSE ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces the ...